Inhibiting OTUB2 for anti-tumor immunity

Inhibiting tumor OTUB2, a deubiquitinating enzyme, could help treat solid tumors by increasing degradation of PD-L1 in the endoplasmic reticulum of tumor cells, and thus increasing anti-tumor immunity.

Bioinformatic analyses of public cancer patient datasets identified tumor OTUB2 as the top deubiquitinating enzyme negatively correlated with a CD8⁺ T cell gene signature, and high OTUB2 mRNA expression was associated with worse patient overall survival and disease-free survival in multiple cancer types. ...